KUKJEON PHARMACEUTICAL Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	135,442	136,468	121,998	103,711	85,354
Other Revenue	-	-0	-	-	-0
Revenue	135,442	136,468	121,998	103,711	85,354
Revenue Growth (YoY)	4.65%	11.86%	17.63%	21.51%	-
Cost of Revenue	115,377	114,594	96,721	84,195	67,409
Gross Profit	20,065	21,874	25,277	19,515	17,946
Selling, General & Admin	15,138	15,327	12,817	11,451	8,699
Research & Development	4,552	4,684	4,821	3,981	2,651
Operating Expenses	21,186	21,507	18,768	16,027	11,836
Operating Income	-1,121	366.71	6,509	3,488	6,109
Interest Expense	-7,773	-8,220	-5,735	-1,802	-284.47
Interest & Investment Income	431.96	878.98	1,591	1,037	208.91
Earnings From Equity Investments	-114.35	-57.48	1.15	301.09	-
Currency Exchange Gain (Loss)	-978.2	-1,655	-253.67	-1,215	-869.65
Other Non Operating Income (Expenses)	11,491	10,498	-391.28	9,279	196.4
EBT Excluding Unusual Items	1,937	1,811	1,722	11,089	5,360
Gain (Loss) on Sale of Investments	2,108	1,831	16.28	67.84	-275.98
Gain (Loss) on Sale of Assets	-49.07	-57.43	-	-69.18	-0
Other Unusual Items	-3,354	-2,706	-	-	-
Pretax Income	642	879.32	1,738	11,088	5,084
Income Tax Expense	323.4	341.65	-2,954	2,210	1,046
Earnings From Continuing Operations	318.6	537.67	4,692	8,877	4,038
Minority Interest in Earnings	1,123	1,199	132	70.7	-
Net Income	1,442	1,736	4,824	8,948	4,038
Net Income to Common	1,442	1,736	4,824	8,948	4,038
Net Income Growth	6.68%	-64.01%	-46.09%	121.59%	-
Shares Outstanding (Basic)	49	49	49	49	44
Shares Outstanding (Diluted)	49	49	49	51	44
Shares Change (YoY)	0.10%	-	-4.23%	16.16%	-
EPS (Basic)	29.35	35.38	98.31	182.35	91.54
EPS (Diluted)	29.35	35.38	98.31	11.35	91.00
EPS Growth	7.05%	-64.01%	766.11%	-87.53%	-
Free Cash Flow	3,031	2,169	-44,269	-29,304	-7,367
Free Cash Flow Per Share	61.71	44.20	-902.17	-571.94	-167.01
Dividend Per Share	10.000	10.000	-	-	-
Gross Margin	14.81%	16.03%	20.72%	18.82%	21.02%
Operating Margin	-0.83%	0.27%	5.33%	3.36%	7.16%
Profit Margin	1.06%	1.27%	3.95%	8.63%	4.73%
Free Cash Flow Margin	2.24%	1.59%	-36.29%	-28.26%	-8.63%
EBITDA	4,143	5,472	9,643	4,932	7,215
EBITDA Margin	3.06%	4.01%	7.90%	4.75%	8.45%
D&A For EBITDA	5,264	5,105	3,134	1,444	1,106
EBIT	-1,121	366.71	6,509	3,488	6,109
EBIT Margin	-0.83%	0.27%	5.33%	3.36%	7.16%
Effective Tax Rate	50.37%	38.85%	-	19.94%	20.58%

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.